Huadong Medicine (000963.SZ): The application for marketing approval of Remifentanil injection has been approved.

Huadong Medicine (000963.SZ) announces that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong") has received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA). The application for the market approval of Remabizine Injection submitted by Zhongmei Huadong has been approved. This drug is an injectable exogenous fluorescent tracer, which needs to be used in conjunction with the transdermal glomerular filtration rate measuring device (TGFR) produced by MediBeacon Inc to evaluate the glomerular filtration rate (GFR) of patients.